

Reimbursement Policy

Policy Number: RPLAB057

Policy Title: Coronavirus Testing in the
Outpatient Setting

Approval Date: Aug. 6, 2026

Effective Date: Dec. 4, 2026

Policy Disclaimer

If a conflict arises between a Reimbursement Policy and any Plan document under which a member is entitled to covered services, the Plan document will govern. If a conflict arises between a reimbursement policy and any provider contract pursuant to which a provider participates in and/or provides covered services to eligible member(s) and/or plans, the provider's contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, Benefit Booklets, Summary Plan Descriptions and other coverage documents. Blue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable Plan documents.

Providers are responsible for submitting accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology (CPT®) Assistant, Healthcare Common Procedure Coding System, ICD-10-CM and ICD-10-PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare & Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services and procedures billed. Claim submissions are subject to claim review, including but not limited to, any terms of benefit coverage, provider contract language, medical policies and reimbursement policies, as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Description

The plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information

This policy only addresses testing for the purpose of medical decision making in the outpatient setting.

This policy does not address work, school, state, or federally mandated SARS-CoV-2 testing.

1. Targeted nucleic acid testing, (e.g., RT-PCR, rapid molecular tests), for COVID-19 (SARS-CoV-2) **may be reimbursable** in any of the following situations:
 - a. For individuals displaying signs and symptoms of possible COVID-19 infection (See **NOTE 1**).
 - b. For asymptomatic individuals with known exposure to COVID-19, **EXCEPT** when the individual has had a previous COVID-19 infection within the last 90 days.
2. For individuals with signs or symptoms of severe acute respiratory syndrome (SARS) who have traveled to endemic areas or who have been exposed to persons with SARS, targeted nucleic acid testing, such as RT-PCR for the detection of SARS coronavirus RNA, **may be reimbursable**.
3. For individuals with signs and symptoms of Middle East respiratory syndrome (MERS) who have traveled to endemic areas or who have been exposed to persons with MERS, targeted nucleic acid testing, such as RT-PCR for the detection of MERS coronavirus RNA **may be reimbursable**.
4. To support a diagnosis of multisystem inflammatory syndrome in children (MIS-C) (see **Note 2**) multisystem inflammatory syndrome in adults (MIS-A) (see **Note 3**) or post-acute sequelae of SARS-CoV-2 infection (PASC), nucleic acid amplification testing and host antibody serology testing **may be reimbursable**.
5. For symptomatic individuals, antigen-detecting diagnostic tests for SARS-CoV-2 (e.g., antigen rapid tests) once every 48 hours **may be reimbursable**.
6. For all other situations not described above, host antibody serology testing **is not reimbursable**.
7. For all situations, neutralization antibody testing for SARS-CoV-2 **is not reimbursable**.

-
8. Testing for other endemic coronaviruses, such as 229E, NL63, OC43, and HKU1, **is not reimbursable.**

NOTE 1: Signs and symptoms associated with a possible COVID-19 infection can include fever, cough, fatigue, shortness of breath or difficulty breathing, congestion or runny nose, chills, muscle or body aches, headache, sore throat, new loss of taste or smell, nausea, vomiting, and diarrhea. (2)

Note 2: According to the CDC, (3) MIS-C is defined as an illness that is found in a person less than 21 years of age when **all** the following conditions are met:

- Subjective or documented fever of at least 38°C;
- Clinical severity requiring hospitalization;
- Evidence of systemic inflammation indicated by C-reactive protein (CRP) ≥ 3.0 mg/dL (30 mg/L);
- New onset of manifestations in at least **two** of the following categories:
 - Cardiac involvement indicated by **one** of the following:
 - Left ventricular ejection fraction $<55\%$,
 - Coronary artery dilatation, aneurysm, or ectasia,
 - Elevated troponin.
 - Mucocutaneous involvement indicated by **one** of the following:
 - Rash,
 - Inflammation of the oral mucosa,
 - Conjunctivitis or conjunctival injection,
 - Extremity findings (e.g., erythema or edema of the hands or feet).
 - Shock.
 - Gastrointestinal involvement indicated by **one** of the following:
 - Abdominal pain,
 - Vomiting,
 - Diarrhea.
 - Hematologic involvement indicated by **one** of the following:
 - Platelet count $<150,000$ cells/ μ L.
 - Absolute lymphocyte count (ALC) $<1,000$ cells/ μ L.

Note 3: According to the CDC, (3), MIS-A is defined as an illness that is found in a person 21 years of age or older when all the following conditions are met:

- Hospitalization for 24 hours or more;
- Subjective or documented fever of at least 38°C for one of the following:
 - 24 or more hours prior to hospitalization;
 - Within the first 3 days of hospitalization.
- No alternative diagnosis (e.g., bacterial sepsis, exacerbation of a chronic medical condition).
- At least **three** of the following (occurring prior to hospitalization or within the first three days of hospitalization), with at least one being a primary clinical criterion:
 - Primary clinical criteria:

- Severe cardiac illness (e.g., myocarditis, pericarditis, coronary artery dilation/aneurysm, new-onset right or left ventricular dysfunction, 2nd/3rd degree A-V block, ventricular tachycardia).
- Rash **and** non-purulent conjunctivitis.
- Secondary clinical criteria:
 - New-onset neurologic signs and symptoms (e.g., encephalopathy in an individual without prior cognitive impairment, seizures, meningeal signs, peripheral neuropathy including Guillain-Barré syndrome).
 - Shock or hypotension not attributable to medical therapy.
 - Abdominal pain, vomiting or diarrhea.
 - Thrombocytopenia (platelet count <150,000/μL).
- Evidence of SARS CoV-2 infection;
- Evidence of systemic inflammation (elevated CRP, ferritin, interleukin-6, erythrocyte sedimentation rate, or procalcitonin).

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Code	Description
86328	IA NFCT AB SARSCOV2 COVID19
86408	NEUTRLZG ANTB SARSCOV2 SCR
86409	NEUTRLZG ANTB SARSCOV2 TITER
86413	SARS-COV-2 ANTB QUANTITATIVE
86769	SARS-COV-2 COVID-19 ANTIBODY
87426	SARSCOV CORONAVIRUS AG IA
87635	SARS-COV-2 COVID-19 AMP PRB
87798	DETECT AGENT NOS DNA AMP
87811	SARS-COV-2 COVID19 W/OPTIC
0224U	ANTIBODY SARS-COV-2 TITER(S)
0226U	SVNT SARSCOV2 ELISA PLSM SRM
0408U	IAAD BLK AC WV BSNSR SARSCV2
U0001	2019-ncov diagnostic p
U0002	Covid-19 lab test non-cdc

CPT copyright 2025 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Centers for Medicare & Medicaid Services. (2026). Healthcare Common Procedure Coding System (HCPCS) Level II.

References

1. CDC. About COVID-19. Updated June 13, 2024. <https://www.cdc.gov/covid/about/index.html>
2. CDC. Symptoms of COVID-19. Updated March 10, 2025. <https://www.cdc.gov/covid/signs-symptoms/>
3. CDC. Multisystem Inflammatory Syndrome: Case Definitions and Reporting. Updated February 19, 2026. <https://www.cdc.gov/mis/hcp/case-definition-reporting/index.html>
4. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. Mar 19 2020;91(1):157-160. doi:10.23750/abm.v91i1.9397
5. WHO. SARS (Severe Acute Respiratory Syndrome). <https://www.who.int/ith/diseases/sars/en/>
6. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). <https://www.who.int/emergencies/mers-cov/en/>
7. WHO. COVID-19 Global Risk Assessment. Updated February 6, 2025. <https://www.who.int/publications/m/item/covid-19-global-risk-assessment>
8. Gandhi R. COVID-19: Clinical features. Updated May 7, 2025. <https://www.uptodate.com/contents/covid-19-clinical-features>
9. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. May 2020;8(5):475-481. doi:10.1016/s2213-2600(20)30079-5
10. WHO. COVID-19 Clinical management: living guidance. Updated November 23, 2021. <https://apps.who.int/iris/bitstream/handle/10665/349321/WHO-2019-nCoV-clinical-2021.2-eng.pdf>
11. Kawasuji H, Takegoshi Y, Kaneda M, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. *PLOS ONE*. 2020;15(12):e0243597. doi:10.1371/journal.pone.0243597
12. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe*. January 1 2021;2(1):E13-E22. doi:10.1016/S2666-5247(20)30172-5
13. Griffin D. Viral Load as a Predictor of COVID-19 Patient Outcomes. Updated December 31, 2020. <https://www.cuimc.columbia.edu/news/viral-load-predictor-covid-19-patient-outcomes>
14. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region. *J Pediatr*. May 13 2020;doi:10.1016/j.jpeds.2020.05.007
15. WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Updated May 15, 2020. <https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>
16. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. May 13 2020;doi:10.1016/s0140-6736(20)31103-x

-
17. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. *Hosp Pediatr*. Apr 7 2020;doi:10.1542/hpeds.2020-0123
 18. Baum SG. Adult Multisystem Inflammatory Syndrome Associated with COVID-19. Updated October 21, 2020. <https://www.jwatch.org/na52622/2020/10/21/adult-multisystem-inflammatory-syndrome-associated-with>
 19. Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. *MMWR Morb Mortal Wkly Rep*. Oct 9 2020;69(40):1450-1456. doi:10.15585/mmwr.mm6940e1
 20. CDC. SARS-CoV-2 Variant Classifications and Definitions. Updated December 1, 2021. <https://stacks.cdc.gov/view/cdc/112177>
 21. CDC. Variants and Genomic Surveillance. Updated August 28, 2025. <https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html>
 22. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Updated November 4, 2025. <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
 23. Corman VM, Lienau J, Witzentrath M. [Coronaviruses as the cause of respiratory infections]. *Internist (Berl)*. Nov 2019;60(11):1136-1145. Coronaviren als Ursache respiratorischer Infektionen. doi:10.1007/s00108-019-00671-5
 24. Ludwig S, Zarbock A. Coronaviruses and SARS-CoV-2: A Brief Overview. *Anesth Analg*. Mar 31 2020;doi:10.1213/ane.0000000000004845
 25. CDC. Overview of Testing for SARS-CoV-2. Updated August 29, 2024. <https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html>
 26. Veroniki AA, Tricco AC, Watt J, et al. Rapid antigen-based and rapid molecular tests for the detection of SARS-CoV-2: a rapid review with network meta-analysis of diagnostic test accuracy studies. *BMC Medicine*. 2023/03/29 2023;21(1):110. doi:10.1186/s12916-023-02810-0
 27. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med*. Mar 16 2020;doi:10.1515/cclm-2020-0285
 28. Chan JF, Yip CC, To KK, et al. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/HeI Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. *J Clin Microbiol*. Apr 23 2020;58(5)doi:10.1128/jcm.00310-20
 29. CDC. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. Updated March 7, 2023. <https://www.fda.gov/media/134922/download>
 30. FDA. Accelerated Emergency Use Authorization (EUA) Summary. Updated June 21, 2022. <https://www.fda.gov/media/136151/download>
 31. Braeye T, Abrams S, Hens N. Factors influencing SARS-CoV-2 IgG test sensitivity: A Bayesian analysis of seroconversion and seroreversion by time since infection, test, age and disease severity. *PLoS One*. 2026;21(2):e0328144. doi:10.1371/journal.pone.0328144
 32. The Native Antigen Company. Why We Need Antigen and Antibody Tests for COVID-19. The Native Antigen Company. Updated March 24, 2020.

<https://thenativeantigencompany.com/why-we-need-antigen-and-antibody-tests-for-covid-19/>

33. Kaduskar O, Gurav YK, Deshpande K, et al. Understanding the dynamics of IgM & IgG antibodies in COVID-19-positive patients. *Indian J Med Res.* May-Jun 2022;155(5&6):565-569. doi:10.4103/ijmr.IJMR_675_21
34. Espejo AP, Akgun Y, Al Mana AF, et al. Review of Current Advances in Serologic Testing for COVID-19. *Am J Clin Pathol.* Aug 5 2020;154(3):293-304. doi:10.1093/ajcp/aqaa112
35. Nayagam SN, Coote W, Carroll MTC, et al. Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research. *The Journal of Infectious Diseases.* 2025;232(1):9-13. doi:10.1093/infdis/jiaf295
36. FDA. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). FDA. Updated January 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>
37. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clinical Infectious Diseases.* 2020;doi:10.1093/cid/ciaa344
38. Li Q, Chen L, Li F, He A. Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and IgM antibodies in recovered patients: a meta-analysis. *BMC Infectious Diseases.* 2023/07/01 2023;23(1):444. doi:10.1186/s12879-023-08425-3
39. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *Bmj.* Jul 1 2020;370:m2516. doi:10.1136/bmj.m2516
40. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics (Basel).* May 19 2020;10(5)doi:10.3390/diagnostics10050319
41. Caturegli G, Materi J, Howard BM, Caturegli P. Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study. *Ann Intern Med.* Oct 20 2020;173(8):614-622. doi:10.7326/m20-2889
42. Fox T, Geppert J, Dinnes J, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database Syst Rev.* Nov 17 2022;11(11):Cd013652. doi:10.1002/14651858.CD013652.pub2
43. NIH. Authorized Tests for COVID-19 and Multiplex Diagnostics. Updated 2026. <https://www.nibib.nih.gov/programs/radx-tech-program/authorized-tests>
44. BD. BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test. Updated July 30, 2025. <https://investors.bd.com/news-events/press-releases/detail/895/bd-receives-fda-510k-clearance-for-rapid-point-of-care-covid-19-test>
45. Diagnostics R. LumiraDx SARS-CoV-2 Ag Test. Updated March 26, 2026. <https://diagnostics.roche.com/us/en/c/lumira-sars-cov-2-ag-test.html>
46. Quidel Corporation. Sofia 2 SARS Antigen FIA. FDA. <https://www.fda.gov/media/137885/download>
47. FDA. In Vitro Diagnostics EUAs. Updated November 8, 2023. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>

-
48. Mathias Weis D, David Ruben Teindl L, Mia E, et al. Preapproval and postapproval diagnostic test accuracy of food and drug administration–authorized rapid antigen SARS-CoV-2 tests used according to instruction: a systematic review and meta-analysis. *Clinical Microbiology and Infection*. 2025;31(10):1630-1638. doi:10.1016/j.cmi.2025.07.009
 49. Seo G, Lee G, Kim MJ, et al. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano*. Apr 28 2020;14(4):5135-5142. doi:10.1021/acsnano.0c02823
 50. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol*. Aug 2020;129:104455. doi:10.1016/j.jcv.2020.104455
 51. Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol*. Aug 2020;129:104500. doi:10.1016/j.jcv.2020.104500
 52. Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol*. Jul 23 2020;58(8)doi:10.1128/jcm.00977-20
 53. Soni A, Herbert C, Lin H, et al. Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection : A Prospective Cohort Study. *Ann Intern Med*. Jul 2023;176(7):975-982. doi:10.7326/m23-0385
 54. Peacock WF, Soto-Ruiz KM, House SL, et al. Utility of COVID-19 antigen testing in the emergency department. *Journal of the American College of Emergency Physicians Open*. 2022;3(1):e12605. doi:10.1002/emp2.12605
 55. FDA. Emergency Use Authorization. Updated December 23, 2024. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>
 56. BioFire. BIOFIRE® Respiratory 2.1 (RP2.1) Panel. BioMerieux. <https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-respiratory-panels.html>
 57. Qiagen GmbH. QIAstat-Dx® Respiratory SARS-CoV2 Panel Instructions for Use (Handbook). <https://www.fda.gov/media/136571/download>
 58. GenMark Diagnostics. ePlex Respiratory Pathogen Panel 2. <https://www.fda.gov/media/142902/download>
 59. FDA. Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. Updated August 5, 2021. <https://www.fda.gov/media/139744/download>
 60. bioMérieux. BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization. Updated March 18, 2021. <https://www.biomerieux.com/us/en/journalists/press-releases/biofirer-respiratory-21-rp21-panel-sars-cov-2-obtains-de-novo-fda-authorization.html>
 61. Qiagen. QIAstat-Dx Respiratory SARS-CoV-2 Panel - Canada. Updated 2026. <https://www.qiagen.com/ca/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-ca#product-details>
 62. Diagnostics R. cobas® eplex respiratory pathogen panel 2. Updated July 2026. <https://diagnostics.roche.com/global/en/products/lab/cobas-eplex-rp-panel-2-pid00000004.html>
 63. CDC. CDC's Influenza SARS-CoV-2 Multiplex Assay. Updated September 2, 2025. <https://www.cdc.gov/flu/php/laboratories/influenza-sars-cov-2-multiplex-assay.html>

-
64. FDA. CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. Updated August 6, 2024. <https://www.fda.gov/media/139743/download>
 65. Poljak M, Korva M, Gašper NK, et al. Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. *Journal of Clinical Microbiology*. 2020;58(6):e00599-20. doi:doi:10.1128/JCM.00599-20
 66. designs B. BIOSYNEX AMPLIQUICK® Respiratory Triplex. Updated 2026. <https://www.biosynex.com/fiches-produit/biologiste-medecin/biologie-moleculaire/ampliquick/virologie/triplex-respiratoire/>
 67. Mboumba Bouassa R-S, Tonen-Wolyec S, Veyer D, Péré H, Bélec L. Analytical performances of the AMPLIQUICK® Respiratory Triplex assay for simultaneous detection and differentiation of SARS-CoV-2, influenza A/B and respiratory syncytial viruses in respiratory specimens. *PloS one*. 2022;17(1):e0262258. doi:10.1371/journal.pone.0262258
 68. Dao Thi VL, Herbst K, Boerner K, et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Science Translational Medicine*. 2020;12(556):eabc7075. doi:10.1126/scitranslmed.abc7075
 69. Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol*. Jul 7 2020;doi:10.1128/jcm.01438-20
 70. Wang R, Qian C, Pang Y, et al. opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection. *Biosensors and Bioelectronics*. 10/26/2020 2020;172:112766. doi:10.1016/j.bios.2020.112766
 71. Hulick P. Next-generation DNA sequencing (NGS): Principles and clinical applications. Wolters Kluwer. Updated January 21, 2026. <https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications>
 72. Helix. Helix COVID-19 NGS Test. <https://www.fda.gov/media/140917/download>
 73. FDA. Illumina COVIDSeq Test. Updated April 22, 2021. <https://www.fda.gov/media/138778/download>
 74. Ahmadi Z, Maleki A, Eybpoosh S, et al. Comparison of a Multiplex Real-Time PCR Technique with Oxford Nanopore Technologies Next-Generation Sequencing for Identification of SARS-CoV-2 Variants of Concern. *Intervirology*. 2023;66(1):136-141. doi:10.1159/000534067
 75. Oude Munnink BB, Nieuwenhuijse DF, Stein M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. *Nature Medicine*. 2020/09/01 2020;26(9):1405-1410. doi:10.1038/s41591-020-0997-y
 76. CDC. About Whole Genome Sequencing. Updated January 8, 2024. <https://www.cdc.gov/pulsenet/php/wgs/>
 77. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus*. Apr 17 2020;12(4):e7708. doi:10.7759/cureus.7708
 78. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. *Clin Microbiol Infect*. Mar 2019;25(3):372-378. doi:10.1016/j.cmi.2018.06.009

-
79. FDA. Accelerated Emergency Use Authorization (EUA) Summary SARS-CoV-2 RT-PCR Assay. <https://www.fda.gov/media/141192/download>
 80. *Pooled Testing and Its Applications in the COVID-19 Pandemic*, bookTitle= *Pandemics: Insurance and Social Protection*. Springer International Publishing; 2022:217--249.
 81. Yelin I, Aharony N, Shaer Tamar E, et al. Evaluation of COVID-19 RT-qPCR test in multi-sample pools. *Clin Infect Dis*. May 2 2020;doi:10.1093/cid/ciaa531
 82. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2. *Jama*. Apr 6 2020;323(19):1967-9. doi:10.1001/jama.2020.5445
 83. WHO. Diagnostic testing for SARS-CoV-2. Updated September 11, 2020. <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>
 84. WHO. "Immunity passports" in the context of COVID-19. Updated April 24, 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
 85. WHO. COVID-19 natural immunity. Updated May 10, 2021. <https://iris.who.int/bitstream/handle/10665/341241/WHO-2019-nCoV-Sci-Brief-Natural-immunity-2021.1-eng.pdf>
 86. WHO. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. Updated March 9, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self_testing-2022.1
 87. WHO. WHO policy brief: COVID-19 testing. Updated December 10, 2024. <https://www.who.int/publications/m/item/who-policy-brief-covid-19-testing>
 88. WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection. Updated September 11, 2021. <https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays>
 89. CDC. Testing for COVID-19. Updated March 10, 2025. <https://www.cdc.gov/covid/testing/index.html>
 90. CDC. Information for Pediatric Healthcare Providers. Updated February 05, 2026. <https://www.cdc.gov/covid/hcp/clinical-care/for-pediatric-hcp.html>
 91. CDC. People with Certain Medical Conditions and COVID-19 Risk Factors. Updated June 11, 2025. <https://www.cdc.gov/covid/risk-factors/index.html>
 92. CDC. Long COVID Basics. Updated March 9, 2026. <https://www.cdc.gov/covid/long-term-effects/>
 93. AMA. Serological testing for SARS-CoV-2 antibodies. American Medical Association. Updated May 14, 2020. <https://www.ama-assn.org/delivering-care/public-health/serological-testing-sars-cov-2-antibodies>
 94. IDSA. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Updated September 6, 2023. <https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/>
 95. IDSA. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. Updated February 9, 2024. <https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/>
 96. Greninger AL, Dien Bard J, Colgrove RC, et al. Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An

-
- Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document. *Clin Infect Dis*. Apr 28 2022;74(8):1496-1502. doi:10.1093/cid/ciab761
97. Talbot TR, Hayden MK, Yokoe DS, et al. Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations. *Infect Control Hosp Epidemiol*. Jan 2023;44(1):2-7. doi:10.1017/ice.2022.295
98. ASA, APSF. ASA and APSF Updated Statement on Perioperative Testing for SARS-CoV-2 in the Asymptomatic Patient. Updated December 21, 2022. <https://www.apsf.org/news-updates/asa-and-apsf-updated-statement-on-perioperative-testing-for-sars-cov-2-in-the-asymptomatic-patient/>
99. Zhang YV, Wiencek J, Meng QH, et al. AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 EUA and LDT Serologic Testing in Clinical Laboratories. *Clinical Chemistry*. 2021;doi:10.1093/clinchem/hvab051
100. ECDC. Diagnostic testing and screening for SARS-CoV-2. European Centre for Disease Prevention and Control. Updated May 30, 2023. <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing>
101. ECDC. Testing strategies for SARS-CoV-2. Updated December 15, 2022. <https://www.ecdc.europa.eu/en/covid-19/surveillance/testing-strategies>
102. ECDC. Guidance for representative and targeted genomic SARS-CoV-2 monitoring. Updated May 3, 2021. <https://www.ecdc.europa.eu/en/publications-data/guidance-representative-and-targeted-genomic-sars-cov-2-monitoring>
103. ECDC. Considerations for the use of antibody tests for SARS-CoV-2 – first update. <https://www.ecdc.europa.eu/en/publications-data/use-antibody-tests-sars-cov-2>
104. Willis ZI, Oliveira CR, Abzug MJ, et al. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. *J Pediatric Infect Dis Soc*. Mar 19 2024;13(3):159-185. doi:10.1093/jpids/piad116
105. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. *Arthritis Rheumatol*. Jul 23 2020;doi:10.1002/art.41454
106. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 2. *Arthritis Rheumatol*. Dec 5 2020;doi:10.1002/art.41616
107. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. *Arthritis & Rheumatology*. 2022;74(4):e1-e20. doi:10.1002/art.42062
108. FDA. Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. Updated March 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-fall-within-enforcement-policies-issued-during-coronavirus-disease>
109. FDA. Transition Plan for Medical Devices Issued Emergency Use Authorizations

(EUAs) Related to Coronavirus Disease 2019 (COVID-19). Updated March 2023.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-issued-emergency-use-authorizations-euas-related-coronavirus-disease>

Policy History

Approval Date	Description
08/06/2026	12/4/2026; Document updated. The following changes were made to Reimbursement Information: revised Notes 2, 3, 4 to align with updated CDC definitions for Covid-19, MIS-C and MIS-A. References revised.
07/25/2025	11/07/2025; Document updated with literature review. The following changes were made to Reimbursement Information: Edited #1 to remove “including rapid molecular tests” as that was duplicative; added “any of” to clarify either of the situations listed were applicable for testing. Removed #6 and #7 as those are addressed on CPCPLAB045 Pathogen Panel Testing. That resulted in the deletion of Note 5. Removed codes 86318 and 87428. References revised.
01/23/2025	04/15/2025; Document updated with literature review. The following changes were made to Reimbursement Information: Added rapid molecular tests as testing option in #1; removed 1c: for asymptomatic individuals prior to undergoing immunosuppressive or aerosol-producing procedures; added NAAT as an acceptable test option for MIS-A and MIS-C in #4; updated #5 to include once every 48 hour frequency; removed #7 and #9 as they are appropriately managed in CPCPLAB045 Pathogen Panel Testing; removed #8 for genotyping. Updated Note 2 with updated CDC signs and symptoms of COVID-19; updated Note 3 and Note 4 with updated CDC clinical requirements for suspected MIS-C and MIS-1. Removed codes 86790, 87631, 87632, 87633, 87797, 87799, 0115U, 0202U, 0223U, 0225U, C9803. References revised.
03/15/2024	Document updated with literature review. Reimbursement information unchanged. References revised; some added, others removed. Removed codes G2023, G2024, U0003, U0004, U0005.
03/01/2024	Added code 0408U. No other changes made.
11/01/2023	Document updated with literature review. Reimbursement information revised for clarity. References revised; some added, others removed.
11/01/2022	New policy